## Business Summary

Flora Growth Corp. operates primarily by growing low-cost, high-quality cannabis in Colombia, where favorable climate and low labor costs allow them to cultivate large quantities efficiently. This raw material is used in two ways: first, it is sold wholesale (B2B) to pharmaceutical companies, distributors, and other manufacturers globally. Second, the company uses it to create its own finished consumer products (B2C), which include beauty brands, wellness supplements, and CBD goods sold directly to general consumers, mainly across North America and Europe. The core of their business model is to use their inexpensive South American cultivation base to supply a diverse, higher-margin portfolio of products worldwide.

---

## Business Model Risk

A significant near-term risk involves regulatory hurdles and licensing delays. Since the cannabis industry is heavily regulated, delays in receiving necessary permits, especially for international export from Colombia, can immediately halt sales and cause inventory issues. This type of risk is common in the industry and has historically led to revenue shortfalls for many cannabis companies. Another immediate concern is the company's reliance on acquired consumer brands for a significant portion of current revenue; if these brands fail to maintain market popularity or if integration costs exceed expectations, overall earnings will suffer quickly. Long-term risks center on the fragmented legal status of cannabis, particularly the ongoing federal illegality in the United States, which limits their access to the largest potential market. Furthermore, political or economic instability in Colombia could disrupt their entire low-cost supply chain, damaging their competitive edge over time.

---

## Company History

This history of Flora Growth Corp. (FLGC) is explained in simple terms, detailing its journey from inception to the present day.

***

### The Founding and Core Goal (Inception)

1.  **Founding Year and Initial Focus:** Flora Growth Corp. was incorporated in March 2019, initially based in Canada, with a core focus on the cultivation, processing, and distribution of medicinal cannabis and its derivatives globally.
2.  **The Founding Vision (Why it was founded):** The company’s main goal was to create a connected group of plant-based wellness and lifestyle brands, powered by exceptionally low-cost cannabis cultivation.
3.  **The Key Innovative Advantage (The Tailwinds):** A major strategy was setting up a massive outdoor cultivation facility, called Cosechemos, in Colombia. The country's ideal climate near the equator and high altitude allow for year-round, organic growing at an ultra-low cost—around **$0.06 per gram**, which is drastically lower than the production costs in North America, which can be over $1 per gram.

### Early Growth and Strategy (2020 - 2022)

4.  **Early Revenue Generation:** The company began generating its first revenues in late 2020, not just from cannabis, but through acquisitions like Flora Beauty and Kasa Wholefoods, which dealt with consumer products like fruit juices.
5.  **Becoming a Public Company:** Flora Growth made a significant step by completing its Initial Public Offering (IPO) in May 2021, listing its shares on the Nasdaq stock exchange.
6.  **The "House of Brands" Strategy (Innovative Solution):** The company adopted a model to diversify its business into three main areas: wholesale cannabis, branded consumer products (House of Brands), and pharmaceutical products. This was a move to avoid relying only on the volatile wholesale market.
7.  **Key Strategic Acquisitions:** To build the "House of Brands," Flora quickly acquired companies like Vessel Brand Inc., a dominant name in high-end cannabis consumption accessories, and signed a licensing deal with the luxury brand Tonino Lamborghini to enter the U.S. CBD beverage market.
8.  **Global Expansion into Pharmaceuticals:** In 2022, the company further solidified its pharmaceutical focus by acquiring Franchise Global Health, which gave them a crucial distribution foothold and operations in Germany—a growing international market for medicinal cannabis.

### Challenges and Recent Shifts (2023 - Present)

9.  **The Headwinds of a Volatile Market:** Despite its low-cost advantage, Flora Growth faced severe financial challenges common in the cannabis sector, including significant revenue declines and operating with a net loss.
10. **Financial and Compliance Problems:** The company's stock price became highly volatile, and it faced the risk of being removed from the Nasdaq stock exchange for its share price falling below the required minimum.
11. **Addressing Financial Compliance (Solution):** To meet the Nasdaq requirement and increase its stock price, the company implemented a **1-for-39 share consolidation** (also known as a reverse stock split) in August 2025. This meant every 39 old shares were combined into one new, higher-priced share.
12. **Major Strategic Shift (Recent Solution):** More recently, the company divested its original Colombian cultivation operations to focus on its higher-margin, core growth areas: the distribution of pharmaceutical products in international markets like Germany and the expansion of its consumer House of Brands in markets like the U.S. and Australia.
13. **Current Status and Outlook:** While the company has improved its net loss position and focuses on cost reduction, its management has cited a "substantial doubt" about its ability to continue operating without securing more funding, highlighting the ongoing difficulty of navigating the global cannabis industry. The company continues its strategic path, including approving a plan to potentially change its name to "ZeroStack Corp." in late 2025.

---

## Moat Analysis

The analysis of Flora Growth Corp. (FLGC) must be split into two parts due to the company's recent, dramatic shift in its business model.

**Phase 1: Flora Growth (The Cannabis/CPG Company - Historical Moat)**

The original business that led to its growth was a diversified cannabis and consumer packaged goods (CPG) entity.

### A. Moat and Differentiation (Historical CPG/Cannabis Focus)

1.  **Cost Advantage (Historical):** The company initially established a moat based on low-cost supply by operating one of the world's largest outdoor cannabis cultivation facilities in Colombia, benefiting from equatorial conditions and low operational costs. This allowed them to produce cannabis at a reported cost of under $0.06 per gram, significantly lower than many competitors.
2.  **Brand Portfolio & Global Distribution:** The core differentiation was not just cultivation, but the acquisition of established brands like **JustCBD** (a leading CBD gummy brand with over 800 products and distribution to all 50 US states) and **Vessel** (a luxury cannabis accessory brand). This built a wide market presence and access to diverse consumer segments (CPG, lifestyle, and high-end accessories).
3.  **Special Market Position (Pharmaceutical):** The acquisition of **Phatebo GmbH** (a German pharmaceutical distributor) created a special position in the European medical market, giving them an established distribution network in 28 countries for medical cannabis and pharmaceutical products, positioning them for European regulatory expansion.
4.  **Growth Driver: Strategic Acquisitions:** The primary reason for its growth was a strategy of acquiring revenue-generating brands and established distribution networks, which rapidly expanded its market reach and product portfolio (e.g., Vessel in North America, Franchise Global Health/Phatebo in Europe).

### B. Pricing Power and Customer Stickiness

1.  **Pricing Power (Brand-Driven):** For the raw cultivation side, pricing power was low due to commodity-like nature, but the **JustCBD** and **Vessel** brands provided some pricing power through brand loyalty and the perception of a high-end, differentiated product experience.
2.  **Customer Stickiness:** The CPG and accessory nature of brands like JustCBD and Vessel, which rely on repeated consumer purchases and strong brand recognition, suggests inherent customer stickiness. Furthermore, the relationships that Vessel built with major US Multi-State Operators (MSOs) for its hardware products also represent recurring B2B contracts.

### C. Vulnerability and Innovation

1.  **Vulnerability to Capital:** Despite the distribution moat, the cannabis segment faced persistent challenges like regulatory headwinds, high compliance costs, and margin compression, which eroded the legacy business and resulted in losses, making the CPG business vulnerable to better-capitalized competitors.
2.  **Investment in R&D/Innovation:** The company pursued innovation in product formulation (e.g., nanoemulsion technology for beverages) and luxury hardware (Vessel), indicating an effort to maintain a product edge, though the historical business unit struggled with overall profitability.

---

**Phase 2: ZeroStack (The AI Treasury Company - New Moat)**

As of late 2025 (according to the search results), Flora Growth has undergone a dramatic strategic pivot, rebranding to **ZeroStack** to become a technology-focused holding company.

### D. New Moat and Differentiation (ZeroStack Focus)

1.  **Total Strategic Pivot:** The company has fundamentally changed its business focus, citing the declining cannabis segment as the primary reason for the shift. The new primary business is a **decentralized AI treasury company**.
2.  **Asset-Based Moat (Digital):** The new moat is based on **strategic ownership of digital assets**, specifically accumulating the **$0G token**, which is the fuel of the 0G distributed AI network (an AI-first blockchain). This positions the company to provide institutional investors with equity-based exposure to AI infrastructure.
3.  **Network Effect (New/Potential):** The defensibility now relies on the potential network effects of the **0G decentralized AI network**. If the 0G blockchain becomes a standard for distributed AI, the company's position as the "first and largest" publicly traded treasury holding its native token will become highly defensible.
4.  **Vulnerability (New):** The new business model is highly vulnerable to two main factors: **digital asset price volatility** (the price of the $0G token) and the **ease of displacement by greater capital** in the volatile crypto/AI markets. The core of the moat is the capital raised and the large-scale investment in a single token.

### E. Current Business Structure

1.  **Hybrid Model:** The company retains a dual focus: the **digital assets treasury** (ZeroStack/0G) and its existing pharmaceutical distribution subsidiary, **Phatebo GmbH**, which acts as a traditional, regulated healthcare revenue stream. The status of the CPG brands (JustCBD, Vessel) remains as operating segments but the strategic focus and capital investment have overwhelmingly shifted to the digital asset treasury.

---

## Catalyst Analysis

The core business and strategic catalysts for Flora Growth Corp. (FLGC) have undergone a significant and recent transformation, shifting from a cannabis-focused company to a technology-centric one.

**Management's Stated Strategy (Q3 2025 Earnings and Recent Releases)**

The management is executing a major strategic pivot:

*   **Strategic Transformation:** The company is moving away from its legacy cannabis and hemp operations, which have been sold, to focus on two core pillars: becoming a **decentralized AI treasury company** and its **global pharmaceutical distribution business** (Phatebo).
*   **Rebranding:** Management is rebranding the company as **ZeroStack Corp.** to emphasize the new focus on decentralized AI and blockchain-based business models.
*   **AI/Digital Asset Focus:** The primary strategy is to build a substantial digital asset treasury, specifically centered on the **$0G (Zero Gravity) token**, which the company calls the "fuel of the 0G Decentralized AI Network." Management is optimistic about leveraging these AI and digital asset investments for future financial performance.

---

## Catalysts for Stock Price Increase

### Near-Term Catalysts (The Transition Phase)

1.  **Rebranding and Name Change Execution:** Formalizing the change to **ZeroStack Corp.** signals the full strategic pivot to the market, which can attract investors focused on the AI and digital asset sectors.
2.  **Expansion of the Digital Asset Treasury:** Continued strategic purchases and positive re-valuations of the $0G token, Solana, and other cryptocurrency holdings on the balance sheet will directly impact the company's reported asset value.
3.  **Completion of Corporate Compliance Actions:** The company successfully regained compliance with the NASDAQ minimum bid price requirement following a 1-for-39 reverse stock split, reducing the risk of delisting.
4.  **Authorized Forward Stock Split:** Shareholders have approved a plan for a forward stock split (between 2:1 and 10:1) within one year, which may be implemented to increase liquidity and make the stock more accessible after the previous reverse split.

### Long-Term Catalysts (The New Business Model)

1.  **Success of Decentralized AI Infrastructure:** The long-term outlook depends heavily on the successful development and commercialization of the decentralized AI infrastructure, which is fueled by the company's $0G token treasury.
2.  **Appreciation of Digital Asset Holdings:** Sustained and significant price appreciation of the $0G token and other strategic crypto investments (like Solana) will directly increase the company's net asset value and valuation.
3.  **Growth in Pharmaceutical Distribution:** Continued organic growth and expansion of the remaining profitable business unit, the global pharmaceutical distributor **Phatebo**, especially within the European market.
4.  **Achievement of Profitability in New Model:** Converting the substantial digital asset investments and the pharmaceutical division's revenue into sustained net income and positive cash flow is the ultimate long-term catalyst.

---

## Management Record

The management of Flora Growth Corp. (FLGC) has undergone a significant and rapid transformation, pivoting the company's core strategy from its cannabis roots to focus on blockchain and AI technology.

### **Current Management & Vision (Focus: AI and Digital Assets)**

1.  **Current Executive Team:** The company's most recent management structure features **Daniel Reis-Faria** as the Chief Executive Officer (CEO) of FLGC ZeroStack, and **Michael Heinrich** as Executive Chairman.
2.  **Strategic Pivot & Rebrand:** The current management is spearheading a radical shift from a cannabis CPG/Pharmaceutical company to a "digital asset treasury (DAT) company" focused on blockchain and Artificial Intelligence (AI). The company is expected to rebrand as **ZeroStack**, maintaining the FLGC ticker.
3.  **Key Decision & Future Strategy:** A central decision was the launch of a $401 million treasury initiative, comprising $35 million in cash and $366 million in digital assets (Zero Gravity or 0G tokens), to support the 0G AI blockchain project. The vision is to offer institutional investors equity-based exposure to a transparent, verifiable, and privacy-first AI infrastructure.
4.  **CEO Background (Daniel Reis-Faria):** Mr. Reis-Faria is a global technology entrepreneur, investor, and diplomat with over fifteen years of experience in AI, blockchain, and cyber-security. He previously served as the founding CEO of OARO, a leading aviation cyber-security company, and facilitated the deal for the first Solana Treasury Vehicle in the U.S..
5.  **Executive Chairman Background (Michael Heinrich):** Mr. Heinrich, a "Forbes 40 under 40" entrepreneur, founded two unicorn companies and runs 0G Labs, the largest AI Layer 1. His background includes experience at Microsoft, SAP Labs, Bain, and Bridgewater Associates.
6.  **CFO's Role (Dany Vaiman):** CFO Dany Vaiman, with nearly two decades of finance and capital markets experience, played a key role in the company's transition to a digital asset treasury company, including the landmark $400 million transaction centered around the AI-driven $0G coin.

### **Recent Performance & Transition History (Focus: Cannabis)**

7.  **High Management Turnover:** Flora Growth has experienced significant CEO turnover, with Clifford Starke succeeding Hussein Rakine in June 2023, and then Starke resigning in September 2025 to be succeeded by Daniel Reis-Faria.
8.  **Performance Under Previous CEO (Clifford Starke):** Starke's management implemented a strategic restructuring which included selling the unprofitable Colombian cultivation entity. This restructuring, along with streamlining the team, led to a reported "best-ever financial results" with a net income of $1.1 million in a recent quarter (Jan 2024 report).
9.  **Track Record of Key Decisions (Starke Era):** The previous strategy concentrated on three core pillars: Vessel (cannabis accessories), the CBD Gummy Division (JustCBD), and Fativa (pharmaceutical distribution in Germany/EU). Starke's stated vision was to be the premier international cannabis company and focus on growth in the US beverage market with a product called Mellow.
10. **Previous Leadership (Luis Merchan):** Prior to Starke's appointment, Luis Merchan served as CEO since 2020 and oversaw the company's initial growth as a cannabis-focused CPG company, including the acquisitions of Vessel and JustCBD.

---

## Management Incentive

Based on the analysis of Flora Growth Corp.'s (FLGC) recent proxy filings and compensation disclosures, here is the assessment of management incentive and compensation:

### **Management Incentive and Compensation Analysis (FLGC)**

#### **1. Insider Ownership**

1.  **Level of Ownership:** Insider ownership by managers and directors stands at approximately **12.54%**.
2.  **Incentive Alignment:** While this is a moderate percentage for a small-cap company, indicating some personal stake in the company's performance, it is not exceptionally high enough to fully secure deep alignment with long-term shareholder interests on its own.

#### **2. Compensation Structure**

1.  **High Compensation for Small-Cap:** Key executives received high total compensation for the 2024 fiscal year, such as the former CEO with over \$2.7 million, and the CFO with over \$1.1 million, for a company with a small market capitalization (around \$6 million in late 2025).
2.  **Equity-Heavy Pay:** The compensation model is heavily reliant on equity-based incentives, including stock options and Stock Appreciation Rights (SARs), confirmed by the recent significant expansion of the company's incentive compensation plan.
3.  **Performance Metrics:** The long-term incentive is partially tied to shareholder value: outstanding SARs had their vesting terms amended to trigger upon **share price increases in 25% increments** from a new, low exercise price (\$0.58 per right). This structure directly rewards management for stock appreciation.

#### **3. Shareholder Alignment and Red Flags**

1.  **Evidence of Shareholder Disapproval (Red Flag):** Shareholders overwhelmingly **voted against** a proposal to grant new Stock Appreciation Rights to the CEO, CFO, and Executive Chairman in June 2025 (with an approximately 6-to-1 vote against), signaling strong disapproval of the proposed executive awards.
2.  **Potential for Dilution (Red Flag):** The company approved a major expansion of the common shares and stock options available under the incentive plan, alongside other share issuances, creating a high risk of **significant shareholder dilution**. The large increase in the share reserve and authorization for a stock split appear to be primarily for capital structure flexibility and executive incentives, which can harm existing shareholders' per-share value.
3.  **Positive Governance Features:** The company maintains a **Clawback Policy** (for incentive pay based on financial reporting measures) and an **Insider Trading Policy** that prohibits hedging and pledging of securities, which are strong mechanisms to mitigate excessive risk-taking and align incentives.

### **Conclusion on Management Incentive**

*   **Mixed Alignment:** Management has a *mixed* incentive structure. The high percentage of compensation derived from stock-based awards (which vest upon stock price appreciation) and the 12.54% insider ownership provide a **direct incentive to increase the stock price** for the benefit of all shareholders.
*   **Risk of Pockets Lining:** The analysis suggests that management may also be incentivized to "line their own pockets" through mechanisms that potentially dilute existing investors. This is evidenced by the massive expansion of the incentive pool and the overwhelming shareholder rejection of proposed equity grants, despite the board's pursuit of a heavy equity compensation model. The overall structure appears to prioritize executive rewards and capital flexibility via dilution, despite clear shareholder dissatisfaction.

---

## Price History

Based on the stock's closing price of approximately **$7.31** (as of December 19-20, 2025) and publicly available technical data, here is an analysis of Flora Growth Corp. (FLGC).

1.  **Current Position vs. 52-Week Low:**
    *   The 52-week range for Flora Growth Corp. is reported as low as **$6.80** and as high as **$47.00**.
    *   The stock is currently trading approximately **7.5%** above its 52-week low of $6.80. (Calculation: (($7.31 - $6.80) / $6.80) * 100% $\approx$ 7.5%).

2.  **Technical Analysis and Trading Low Status:**
    *   Based on multiple moving average indicators (5-day, 20-day, 50-day, 200-day), the stock is currently flashing a technical signal of **"Strong Sell."**
    *   It is considered to be in a "very wide and falling trend" and holds sell signals from both short- and long-term moving averages, indicating a negative forecast.
    *   The stock's current price is significantly below its major moving averages, such as the 50-day simple moving average (SMA) of $10.60 and the 200-day SMA of $20.32, which technically suggests it is trading quite low relative to its recent trends.

3.  **Recent Significant Drops and Explanation:**
    *   The stock has seen a sharp decline over the past year, being down approximately **-82.19%** over the last 12 months.
    *   One notable drop was a roughly **15% fall** in April 2024 following the announcement of a **secondary offering** to raise cash, which often causes dilution of existing shares.
    *   It also experienced a multi-day decline in mid-December 2025, falling about **-27.98%** over a 10-day period, driven by volatility and a broader "risk-off sentiment" in the cannabis and speculative small-cap sectors.

4.  **Significant Rises and Corporate Activity:**
    *   The stock had a significant bounce of **26%** in the month leading up to September 2025, despite a struggling longer-term performance.
    *   In September 2025, the company announced a **$401 million funding agreement**, which included a $22.88 million investment from Defi Development, helping to provide a short-term boost.
    *   In late 2025, the company shifted its strategic focus, which included an investment into the **cryptocurrency and blockchain sector** and a pivot to a **decentralized AI treasury** (ZeroStack).
    *   In December 2025, shareholders approved nine proposals, including the formalization of the **AI-focused capital structure shift**, which led to a sharp surge in after-hours trading.

---

## Long Thesis

The bull case for Flora Growth (soon to be ZeroStack) rests entirely on its radical pivot from an unprofitable cannabis company to a publicly traded 'AI Treasury' company. The company used its remaining capital to accumulate a massive holding of digital assets—specifically the foundational tokens for the Zero Gravity (0G) decentralized AI network. In the near term, this pivot immediately reduces regulatory complexity and attracts a new class of investors focused on high-growth technology and cryptocurrency exposure. The existing, regulated German pharmaceutical distribution business provides a stable, traditional revenue floor during the transition. In the long term, the thesis is straightforward: if the 0G AI network becomes a successful and widely adopted infrastructure layer for decentralized computing, the value of the company's substantial digital asset treasury will surge. Because the company’s valuation will be tied to the appreciation of these held digital assets, this appreciation will rapidly increase the company’s total net asset value and, subsequently, the stock price, providing equity investors a unique, publicly traded way to benefit from the growth of cutting-edge AI technology.

---

## Long Thesis Assumptions

The core assumption is the successful adoption and exponential growth of the underlying AI network (0G) and the resulting sharp appreciation in value of the digital assets (tokens) the company holds. It is also assumed that the new management team, which has strong backgrounds in technology and blockchain, can successfully navigate the highly volatile digital asset markets. Finally, the traditional public market (NASDAQ) must accept and value this company based on the worth of its volatile digital asset holdings, rather than demanding traditional revenue and profit growth from its legacy consumer product divisions.

---

## Bear Case Scenario

This critique identifies several significant flaws and risks in the bull thesis for Flora Growth Corp. (FLGC), soon to be ZeroStack.

## Bear Case Thesis for Flora Growth Corp. (FLGC) / ZeroStack

The bull case is fundamentally flawed because it relies on the pre-listing valuation of an unproven digital asset that has since sharply depreciated and overstates the stability of the legacy business. The primary risks for equity holders are extreme volatility, massive hidden dilution, and a failed pivot if the core digital asset doesn't return to its Private Investment in Public Equity (PIPE) valuation.

### Flaws and Faults in the Long Thesis

1.  **Massive Overvaluation and Depreciation of the Core Digital Asset (0G):** The bull case's central pillar—the "$401 million treasury"—is misleading, as $366 million was contributed "in-kind" with $0G tokens at an assumed price of **$3.00 per token**. Post-listing, the $0G token's market price has been reported around **$0.80**, representing a roughly **73% loss in value** of the company's largest asset since the PIPE transaction closed.

2.  **Severe Dilution Risk from PIPE and Capital Restructuring:** The $401 million PIPE resulted in new common shares and the authorization of new issuances tied to **pre-funded warrants** and **convertible notes**. Shareholders also approved a massive expansion of the Incentive Compensation Plan (stock options) and an authorization for a **forward share split of up to 10-for-1**. This indicates substantial potential dilution for existing shareholders to compensate for the capital raise and management incentives under the new strategy.

3.  **The "Stable Revenue Floor" is a Loss-Making Going Concern:** The assertion that the "existing, regulated German pharmaceutical distribution business [Phatebo GmbH] provides a stable, traditional revenue floor" is contradicted by the company's historical financials. The legacy operations were part of a company that reported a **net loss of $15.9 million** (FY 2024) and whose management had previously raised "substantial doubt about the company's ability to continue as a going concern," indicating a financially weak base for the pivot.

4.  **Equity Valuation is Tied to the Volatility of an Unproven Crypto Project:** The entire bull case shifts the company from a complex but tangible business to a highly speculative "AI Treasury." The company's valuation is now directly dependent on the price action of a **single, foundational-stage Layer 1 blockchain token ($0G)**, which has a short price history and an unproven long-term utility, exposing equity investors to the extreme, regulatory-uncertain volatility of the cryptocurrency market.

5.  **New Management's Track Record in Volatile Assets is Unproven:** While the new management has strong backgrounds in technology and blockchain, the successful transition and long-term asset management of a publicly traded company whose primary asset is a highly volatile, unproven token (especially one that has already dropped significantly from the private placement price) is a massive execution risk for the new team. [cite: 7 in step 1]

---

## Next Steps

The analysis has revealed a massive and unprecedented strategic pivot, but the success hinges entirely on a few highly volatile and unquantified factors. The most critical unanswered questions revolve around the true value of the core digital asset and the actual, *current* financial standing after its value plunge.

Here are the next important questions to investigate:

1.  **Determine the Current Net Asset Value (NAV) Per Share:**
    *   The original $401 million treasury valuation is based on an $0G token price of up to $3.00, but the token has been reported to have dropped dramatically, with subsequent purchases at $2.59 and $2.27.
    *   **Question:** What is the most recent reported market price and liquidity of the $0G token, and what is the resulting actual estimated Net Asset Value (NAV) per share based on the most recent share count and digital asset holdings? (The most recent disclosed calculation was **$23.22 per share** based on a $1.87 token price in October 2025, a significant drop from the initial valuation, and the current token price is likely even lower.)

2.  **Verify the Actual Status of the Strategic Dilution:**
    *   Shareholders approved the issuance of common shares for the private placement warrants/notes and authorized a massive increase in the incentive plan and a **forward stock split** of 2:1 to 10:1.
    *   **Question:** Has the Board of Directors actually *executed* the authorized forward stock split, issued the shares underlying the pre-funded warrants/convertible notes, or begun selling the newly authorized incentive shares, which would dramatically impact the current share count and dilution risk?

3.  **Investigate the 0G Decentralized AI Network (The Core Asset):**
    *   The entire bull case depends on the **0G** network becoming a successful distributed AI infrastructure.
    *   **Question:** What is the 0G network's current development stage (e.g., testnet/mainnet launch status, partnerships, and developer adoption), and what is the total *fully diluted* supply of $0G tokens compared to the company's treasury holdings?

4.  **Confirm the Status of the Legacy "Stable Revenue" Business (Phatebo):**
    *   The pharmaceutical distribution unit, Phatebo GmbH, is cited as a stable floor, but the company reported a net loss and a going concern warning for its legacy operations.
    *   **Question:** Is the pharmaceutical distribution business, Phatebo GmbH, still an **operational** core pillar, and what is its specific, most recent quarterly revenue and profitability *after* the company divested its other consumer brands (JustCBD, Vessel)?

5.  **Examine Insider Trading Post-Pivot:**
    *   The new management is crypto-focused, and their incentives are tied to the stock price.
    *   **Question:** What have the key new executives (CEO Daniel Reis-Faria and Executive Chairman Michael Heinrich) been doing with their company stock or options since the strategic pivot and the approval of new equity grants in December 2025? (Look for recent Form 4 filings).